Insider Selling: Vera Therapeutics (NASDAQ:VERA) CEO Sells $679,690.00 in Stock

Vera Therapeutics, Inc. (NASDAQ:VERA) CEO Marshall Fordyce sold 18,500 shares of the business’s stock in a transaction dated Tuesday, May 12th. The stock was sold at an average price of $36.74, for a total transaction of $679,690.00. Following the completion of the sale, the chief executive officer owned 216,744 shares in the company, valued at approximately $7,963,174.56. This trade represents a 7.86% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Marshall Fordyce also recently made the following trade(s):

• On Tuesday, April 14th, Marshall Fordyce sold 22,951 shares of Vera Therapeutics stock. The stock was sold at an average price of $44.05, for a total transaction of $1,010,991.55.
• On Monday, February 23rd, Marshall Fordyce sold 16,925 shares of Vera Therapeutics stock. The shares were sold at an average price of $41.98, for a total transaction of $710,511.50.

Vera Therapeutics Stock Performance

Shares of NASDAQ:VERA opened at $37.32 on Friday. The company has a market capitalization of $2.68 billion, a price-to-earnings ratio of -6.74 and a beta of 0.96. Vera Therapeutics, Inc. has a 12 month low of $18.76 and a 12 month high of $56.05. The firm’s 50-day moving average is $39.59 and its 200 day moving average is $40.61. The company has a current ratio of 13.64, a quick ratio of 13.64 and a debt-to-equity ratio of 0.15.

Vera Therapeutics (NASDAQ:VERA) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($1.69) EPS for the quarter, missing the consensus estimate of ($1.33) by ($0.36). During the same quarter in the prior year, the company posted ($0.81) EPS. Research analysts predict that Vera Therapeutics, Inc. will post -5.9 EPS for the current year.

Institutional Investors Weigh In On Vera Therapeutics

Several hedge funds have recently modified their holdings of the business. SummitTX Capital L.P. purchased a new stake in shares of Vera Therapeutics in the 1st quarter worth approximately $814,000. Orbimed Advisors LLC lifted its position in shares of Vera Therapeutics by 4.6% in the 1st quarter. Orbimed Advisors LLC now owns 369,596 shares of the company’s stock worth $14,869,000 after purchasing an additional 16,096 shares during the period. Renaissance Technologies LLC lifted its position in shares of Vera Therapeutics by 136.5% in the 1st quarter. Renaissance Technologies LLC now owns 457,300 shares of the company’s stock worth $18,397,000 after purchasing an additional 263,900 shares during the period. Sei Investments Co. lifted its position in shares of Vera Therapeutics by 114.2% in the 1st quarter. Sei Investments Co. now owns 13,001 shares of the company’s stock worth $523,000 after purchasing an additional 6,932 shares during the period. Finally, Walleye Capital LLC lifted its position in shares of Vera Therapeutics by 50.1% in the 1st quarter. Walleye Capital LLC now owns 23,156 shares of the company’s stock worth $932,000 after purchasing an additional 7,730 shares during the period. Hedge funds and other institutional investors own 99.21% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the stock. HC Wainwright upped their price target on shares of Vera Therapeutics from $90.00 to $110.00 and gave the company a “buy” rating in a report on Monday, March 2nd. Wolfe Research raised shares of Vera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $88.00 price objective for the company in a research report on Wednesday, March 11th. Evercore set a $91.00 price objective on shares of Vera Therapeutics in a research report on Friday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Vera Therapeutics in a research report on Monday, April 20th. Ten investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $79.00.

About Vera Therapeutics

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.